Success Story: NIW Victory without RFE! An Oncology Bioinformatics Expert Achieves Success
Client’s Testimonial:
"Thank you so much!!!!! I was so happy to see the approval email over the weekend. Really appreciate your help on this journey."
On May 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist, Oncology Bioinformatics in the Field of Oncology Bioinformatics (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: Sientist, Oncology Bioinformatics
Country of Origin: South Korea
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: May 9th, 2026
Processing Time: 9 months, 10 days
Case Summary:
This approval reflects our firm's dedication to crafting well-supported, strategically compelling petitions for high-achieving researchers worldwide. We are pleased to share the success of an EB-2 NIW (National Interest Waiver) petition for a scientist in biomedical sciences from South Korea. Holding a Ph.D. in biological and biomedical sciences, this researcher secured approval by demonstrating that their work carries both substantial merit and national importance to the United States.
Our firm successfully argued that contributions to multi-omics cancer data analysis, germline variant detection, and precision cancer therapy development directly support critical national priorities in public health, precision medicine, and U.S. technological leadership in biotechnology and bioinformatics.
Research Focus and National Importance
The proposed endeavor focuses on developing and applying state-of-the-art bioinformatic methods to extract key biological and genetic insights from large-scale multi-omics cancer data, intending to advance treatment strategies and improve patient outcomes. By leveraging cutting-edge computational tools and multi-omics datasets, this research accelerates tumor characterization and the development of precision cancer therapies across a wide range of cancer types.
This work holds clear national importance. Cancer remains one of the most urgent public health challenges in the United States, and the need for innovative, data-driven approaches to detection, prevention, and treatment has never been greater. This research directly addresses these challenges, while also advancing biotechnology, bioinformatics, and computational biology, areas recognized as critical to U.S. technological leadership, national security, and long-term competitiveness.
Demonstrating Influence Through Research Impact
To demonstrate that this researcher is well-positioned to advance the proposed endeavor, our firm presented a strong and documented record of scholarly achievement. The portfolio includes 11 peer-reviewed journal articles (1 of them first-authored), 6 abstracts, and 2 preprints. The work has been cited 505 times.
Beyond publications, this researcher has been regularly invited to conduct peer reviews for leading journals in oncology, genomics, and bioinformatics, and has completed at least 11 reviews to date, reflecting the scientific community's recognition of this researcher as a trusted expert in the field. The research has further received competitive funding from the National Institutes of Health, the National Cancer Institute, the Department of Defense, the Mark Foundation for Cancer Research, the Prostate Cancer Foundation, and the Fund for Innovation in Cancer Informatics, serving as meaningful external validation of the work's significance and its direct alignment with U.S. national health priorities.
The Result
With our firm's strategic preparation and careful framing of the petition, approval was granted in over 9 months without RFE. This outcome reflects both the strength of the contributions presented and our team's expertise in showcasing complex scientific work in the most compelling light. We are proud to have supported this dedicated researcher and extend our sincere best wishes for continued success in advancing cancer research and improving patient outcomes across the United States.